A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin

R. B. Nussenblatt, M. D. De Smet, B. Rubin, V. Freidlin, S. M. Whitcup, Janet L Davis, D. Herman, J. N. Bloom, P. K. Sran, S. Whitcher, A. Palestine, H. Austin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.

Original languageEnglish
Pages (from-to)583-591
Number of pages9
JournalAmerican Journal of Ophthalmology
Volume115
Issue number5
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Uveitis
Cyclosporine
Body Weight
Visual Acuity
Kidney
Macular Edema
Therapeutics
Prednisone
Pharmaceutical Preparations
cyclosporin G
Liver

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. / Nussenblatt, R. B.; De Smet, M. D.; Rubin, B.; Freidlin, V.; Whitcup, S. M.; Davis, Janet L; Herman, D.; Bloom, J. N.; Sran, P. K.; Whitcher, S.; Palestine, A.; Austin, H.

In: American Journal of Ophthalmology, Vol. 115, No. 5, 01.01.1993, p. 583-591.

Research output: Contribution to journalArticle

Nussenblatt, RB, De Smet, MD, Rubin, B, Freidlin, V, Whitcup, SM, Davis, JL, Herman, D, Bloom, JN, Sran, PK, Whitcher, S, Palestine, A & Austin, H 1993, 'A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin', American Journal of Ophthalmology, vol. 115, no. 5, pp. 583-591.
Nussenblatt, R. B. ; De Smet, M. D. ; Rubin, B. ; Freidlin, V. ; Whitcup, S. M. ; Davis, Janet L ; Herman, D. ; Bloom, J. N. ; Sran, P. K. ; Whitcher, S. ; Palestine, A. ; Austin, H. / A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. In: American Journal of Ophthalmology. 1993 ; Vol. 115, No. 5. pp. 583-591.
@article{fe2d090d5366440889a706d474acb929,
title = "A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin",
abstract = "Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.",
author = "Nussenblatt, {R. B.} and {De Smet}, {M. D.} and B. Rubin and V. Freidlin and Whitcup, {S. M.} and Davis, {Janet L} and D. Herman and Bloom, {J. N.} and Sran, {P. K.} and S. Whitcher and A. Palestine and H. Austin",
year = "1993",
month = "1",
day = "1",
language = "English",
volume = "115",
pages = "583--591",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin

AU - Nussenblatt, R. B.

AU - De Smet, M. D.

AU - Rubin, B.

AU - Freidlin, V.

AU - Whitcup, S. M.

AU - Davis, Janet L

AU - Herman, D.

AU - Bloom, J. N.

AU - Sran, P. K.

AU - Whitcher, S.

AU - Palestine, A.

AU - Austin, H.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.

AB - Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.

UR - http://www.scopus.com/inward/record.url?scp=0027173101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027173101&partnerID=8YFLogxK

M3 - Article

C2 - 8488909

AN - SCOPUS:0027173101

VL - 115

SP - 583

EP - 591

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -